EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Chimeric antigen receptor‐engineered adoptive cell therapy for AML: Current status and future perspectives

Yue Huang, Mi Shao, Yiyun Wang, He Huang

ImmunoMedicine · 2022

DOI: 10.1002/imed.1031 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ImmunoMedicine, 2022. Verfasst von Yue Huang und 3 weiteren Autor:innen. Die Arbeit nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute myeloid leukemia (AML) is one of the lethal hematological malignancies with high relapse rates and poor prognosis. Since chimeric antigen receptor cellular therapy has exhibited remarkable therapeutic outcomes in B‐cell malignancies, many studies have attempted to translate this success to other malignancies, including AML. Herein we review current achievements of chimeric antigen receptor‐based cell therapy in AML preclinical studies and clinical trials with potential AML‐associated cell markers. Furthermore, we discuss future prospects of chimeric antigen receptor‐based cell therapy options for patients with AML.

Zitieren

APA

Huang, Y., Shao, M., Wang, Y., & Huang, H. (2022). Chimeric antigen receptor‐engineered adoptive cell therapy for AML: Current status and future perspectives. ImmunoMedicine. https://doi.org/10.1002/imed.1031

Vancouver

Huang Y, Shao M, Wang Y, Huang H. Chimeric antigen receptor‐engineered adoptive cell therapy for AML: Current status and future perspectives. ImmunoMedicine. 2022. doi:10.1002/imed.1031

BibTeX
@article{Huang2022,
  author = {Huang, Yue and Shao, Mi and Wang, Yiyun and Huang, He},
  title = {Chimeric antigen receptor‐engineered adoptive cell therapy for AML: Current status and future perspectives},
  journal = {ImmunoMedicine},
  year = {2022},
  doi = {10.1002/imed.1031}
}
Kostenlos starten →